| 21.15 2.91 (15.95%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 27.31 | 1-year : | 31.27 |
| Resists | First : | 23.38 | Second : | 26.77 |
| Pivot price | 20.05  |
|||
| Supports | First : | 17.89 | Second : | 14.89 |
| MAs | MA(5) : | 19.3 |
MA(20) : | 20.83 |
| MA(100) : | 20.88 |
MA(250) : | 13.13 |
|
| MACD | MACD : | -1.2 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 27.8 |
D(3) : | 18.7 |
| RSI | RSI(14): 49.7 |
|||
| 52-week | High : | 28.44 | Low : | 2.15 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ANRO ] has closed below upper band by 23.9%. Bollinger Bands are 15.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 21.24 - 21.35 | 21.35 - 21.45 |
| Low: | 17.76 - 17.85 | 17.85 - 17.95 |
| Close: | 20.97 - 21.15 | 21.15 - 21.32 |
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Wed, 03 Jun 2026
ANRO: Three late-stage psychiatry programs expect pivotal data readouts in 2027 - TradingView
Fri, 29 May 2026
Alto Neuroscience (ANRO) director awarded 26,000 stock options at $20.44 strike price - Stock Titan
Fri, 29 May 2026
Alto Neuroscience (ANRO) director Andrew Craig Miller files initial Form 3 - Stock Titan
Thu, 28 May 2026
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors - Business Wire
Thu, 28 May 2026
Biotech leader Andrew Miller joins Alto Neuroscience (ANRO) board and governance committee - Stock Titan
Fri, 15 May 2026
Alto Neuroscience (ANRO) CEO gifts 400,000 shares to family trust - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 35 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 4.5 (%) |
| Held by Institutions | 82 (%) |
| Shares Short | 1,610 (K) |
| Shares Short P.Month | 2,190 (K) |
| EPS | -2.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.94 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.8 % |
| Return on Equity (ttm) | -38.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -62 (M) |
| Levered Free Cash Flow | -40 (M) |
| PE Ratio | -8.71 |
| PEG Ratio | 0 |
| Price to Book value | 3.04 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.92 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|